Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Growth and Trends 2020

The worldwide Idiopathic Thrombocytopenic Purpura Therapeutics Market is projected to attain nearly USD 566 million by 2020. It can expand at a 5.9 % CAGR over the forecast period (2014-2020). The market stood at around USD 382 million in 2013. It is driven by favorable government policies such as the U.S. Orphan Drug Act. Demand of combination therapies like dexamethasone and TPO-RA is another factor which may influence market growth.

ITP (idiopathic thrombocytopenic purpura) is a rare disease with low affliction rates. This disease leads to excessive bruising or bleeding due to the lack of blood platelets. It is also known as immune thrombocytopenia and can affect children and adults alike. ITP affects nearly 0.3% out of every 100,000 in the U.S. Commercialization of new drugs like IVIG3I 10% and Avatrombopag is anticipated to propel demand over the forecast period.

Browse Details of Report @ https://www.hexaresearch.com/research-report/idiopathic-thrombocytopenic-purpura-itp-therapeutics-industry

The global Idiopathic Thrombocytopenic Purpura Therapeutics Market is segmented according to products and regions. As per products, the classifications are TPO-RA (thrombopoetin receptor agonist), anti-D immunoglobulin, intravenous immunoglobulin (IVIG), anti-D immunoglobulins, corticosteroids, and others. Corticosteroids were valued over USD 125 million in 2013 and are the most widely preferred drug for treating ITP. Its high share in overall revenues can be attributed to its low price. TPO-RA can experience surging demand on account of commercialization of Avatrombopag.  This can be attributed to the use of TPO-RA in splenectomized patients suffering relapses. Avatrombopag can act as a second line of defense due to its positive clinical trial results.
High response rates displayed by patients administered with Eltrombopag and Romiplostim can positively impact the TPO-RA segment till 2020. Other therapeutic classes are interferon, immunosuppressant, and monoclonal antibodies (mAbs). mAbs such as Rituximab were used frequently in Europe till 2013. However, patent expiry of the same has created scope for drug manufacturers to develop biosimilars.

North America, Europe, Asia Pacific, and RoW (Rest of the World) are regional segments of the worldwide ITP market. North America led the overall industry in 2013 owing to favorable government initiatives, rising ITP cases, and high research funding. Clinical trials based on combination therapy and drug developments are expected to spur regional demand over the forecast period. North America had a revenue share exceeding 40% in 2013.

Europe was the second largest market in 2013 propelled by high product penetration and favorable initiatives pertaining to its production. Asia Pacific is expected to prosper considerably over the next 6 years due to the untapped markets in India and China. Furthermore, sophisticated healthcare and government initiatives in Australia and Japan can contribute significantly to regional demand. 

Notable players of the Idiopathic Thrombocytopenic Purpura Therapeutics Market are Grifols Biologicals Inc.; GlaxoSmithKline (GSK) Plc; Amgen Inc.; and F. Hoffman-La Roche AG. These companies invest robustly in research and development to launch newer products in order to sustain their respective market shares.

GSK recently got approval for its trademark product “Revolade™” by Health Canada, the department of the government of Canada that looks into national public health. This product is a capsule which needs to be taken orally to treat ITP. It can help boost production of blood platelets. Amgen Inc.’s “Nplate” helps restore blood platelets in children. It can act as a viable alternative to treat severe bleeding concurrent with ITP. This drug had generated nearly USD 400 million in 2013. Although Promacta and Nplate received approvals at the same time, the former is expected to dominate the market in the near future.

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/pharmaceuticals-industry

Medical Specialty Bags Market Drivers and Key Opportunities 2020

Growing geriatric population and patient awareness are two vital factors that propel the global MedicalSpecialty Bags Market. Urinary incontinence & dissoluteness are commonly occurring problems among the elderly; especially those above 60 years of age. Thus, the growing need for effective solutions to tackle this age-related problem could positively impact the overall industry from 2012 to 2020 (forecast period). Surging expenditure on healthcare also supports the industry.

Medical specialty bags are products that help curb & manage problems that stem from conditions, such as bile leakage and bowel incontinence. The performance of the global market depends significantly on new product innovation and technological advancements. The need for specialty bags arises during surgical procedures, such as laparoscopic surgeries and urinary surgical procedures. Moreover, high incidence of cancer, cardiovascular disorders, and cancer fuel industry demand.

The worldwide medical specialty bags market is categorized as per products, applications, and geographies. Based on products, the categories are cadaver bags, ice bags, intravenous fluid bags, ostomy collection bags, CAPD (continuous ambulatory peritoneal dialysis) bags, enema bags, resuscitation bags, blood bags, enteral feeding bags, sterile packaging bags, bile collection bags, urinary collection bags, and anesthesia breathing bags. Ostomy collection bags are ideal for patients suffering from urinary dissoluteness. This product segment is expected to witness high demand over the forecast period.

Browse Details of Report @ https://www.hexaresearch.com/research-report/medical-specialty-bags-industry

The global market is characterized by continuous improvements in medical standards & facilities. Such a trend could have a positive impact on product demand in the forthcoming years. Furthermore, heightened awareness among the masses not just about health but also hygiene may fuel the medical specialty bags industry in the years to come. As per applications, the segments are SurgiCenters, hospitals & medical centers, and home healthcare. Due to widespread awareness and surging demand, SurgiCenters may augment industry growth.

Geographically, the global market is divided into Asia Pacific, North America, Europe, and Rest of the World (RoW). Owing to high disposable incomes and rising per capita spending on healthcare, North America dominates the overall market. Other regional drivers are advanced healthcare infrastructure and implementation of several government initiatives. The active participation of NGOs has also played a vital role in supporting the North America market. The region contributed to more than 42% of overall revenues in 2013. However, current industry trends suggest that Asia Pacific may lead the global industry till 2020. Factors that drive this region are economic development, favorable government initiatives, and growing geriatric population.

Key companies in the global medical specialty bags market are Pall Corporation, Westfield Medical Ltd., B Braun Medical, Coloplast A/S, and Terumo Corporation. PVC (polyvinyl chloride) is the most commonly used material in the bag & tubing industry. However, there are a number of OEMs (original equipment manufacturers) that seek alternative materials to replace PVC. Ethylene vinyl acetate (EVA) polymers generally do not need plasticizers. Ateva® G EVA polymers manufactured by Celanese Corporation is a widely accepted product in parenteral nutrition bag applications. This product is ideal for OEMs that aim at offering nutrition bags that are 100% non PVC-based. Celanese Corporation is a Fortune 500 specialty materials company based in Texas, U.S.

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/medical-devices-industry

Tissue Engineering Market Size to Exceed USD 94.7 billion by 2024

The global Tissue Engineering Market stood at USD 5.5 billion in 2015 and is expected to witness considerable growth even over the forecast period (from 2016 to 2024). Growing needs to bridge the gap between organ demand & supply are expected to drive the industry demand in the near future. Growing popularity in a variety of sectors including urological products, neurology, burn treatment etc. is also anticipated to boost the market growth. Organs developed using this method have high efficiency and durability. Rising applications of this method from surgical treatment of tissues and prosthetics to liver, corneal, cardiac tissue engineering is said to propel the growth from 2016 to 2024. The global market is categorized as applications and regions.

The applications include GI & gynecology, cancer, cord blood & cell banking, skin or integumentary, urology, dental, musculoskeletal, spine, orthopedics, neurology, and cardiology & vascular. The orthopedic application sector occupied more than half of the total market share in 2015. The sector is further expected to continue leading the market on account of the increased number of bone implants due to accidents as well as a geriatric population base. The neurology sector is one of the fastest-growing application sectors since it has the wider scope for development. In addition to this, a significant amount of research in the neurology sector is also anticipated to drive the sector growth.

Browse Details of Report @ https://www.hexaresearch.com/research-report/tissue-engineering-market

Regionally, North America dominated the global tissue engineering market in 2015 accounting for the largest share. It is further projected to continue its dominance even during the forecast period. This can be attributed to the presence of leading players in the region and high financial support for R&D from the government as well as some private organizations. The Asia-Pacific region is expected to be the most lucrative region in the near future. This is mainly because of the existence of immense manpower and highly developed procedures coupled with government funding. The European market is said to register reasonable growth prospects due to the presence of stringent regulatory rules.
Major players in the tissue engineering market are acquiring and working in partnerships with small-scale companies so as to influence technology & research advancements and to expand the product portfolio. Some of the key players include Sanofi S. A.; CryoLife Inc.; StemCells Inc.; and BioMimetic Therapeutics Inc.


Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/healthcare-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com
Website - http://www.hexaresearch.com/